Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143514 · ClinicalTrials.gov registry record
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
A clinical trial of Relapsing Multiple Sclerosis, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- 16
- Enrollment target
- 4
- Study locations
NCT06143514: Recruiting study of Relapsing Multiple Sclerosis, sponsored by TG Therapeutics.
NCT06143514 is a study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 16 participants, below the 2,169-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06143514, a study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (4)
California
- PROVIDE Virtual Research Coordination Center - San Francisco
Georgia
- PROVIDE Virtual Research Coordination Center - Smyrna
North Carolina
- PROVIDE Virtual Research Coordination Center - Wilmington
Tennessee
- PROVIDE Virtual Research Coordination Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2026-06-30 |
What NCT06143514 shows while recruiting
NCT06143514 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 2,169-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT06143514 reports a single indexed study location in California, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06143514 about?
NCT06143514 is a clinical study titled "A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk". The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
What is the current status of trial NCT06143514?
This trial is currently recruiting. The enrollment target is 16 participants. The study started on 2024-03-26. Estimated completion is 2026-06-30.
What conditions does trial NCT06143514 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06143514?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT06143514?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143514 being conducted?
This trial has 4 study locations across California, Georgia, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06143514's enrollment target sits among peer trials
16 24th of 23 the lowest of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
RECRUITING · Phase 4
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI